Stronger warning about potential hepatotoxicity in patients taking Duract (bromfenac)
March 1998
The FDA is requiring a stronger warning about potential hepatotoxicity in patients taking Duract (bromfenac). Duract is the new NSAID that just came out last fall. It's approved only for short-term use...similar to Toradol (ketorolac).
Now there are several reports of severe hepatitis and liver failure in patients taking Duract for longer than a month.
Don't prescribe Duract for more than 10 days. If patients take it longer, monitor LFTs...particularly ALT and bilirubin.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote